Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,489 | 437 | 2,985 |
| Samples | 1,044 | 194 | 829 |
| Peptides | 1,005 | 171 | 868 |
Function
PTPRS · Protein tyrosine phosphatase receptor type S
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular region, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus represents a receptor-type PTP. The extracellular region of this protein is composed of multiple Ig-like and fibronectin type III-like domains. Studies of the similar gene in mice suggested that this PTP may be involved in cell-cell interaction, primary axonogenesis, and axon guidance during embryogenesis. This PTP has been also implicated in the molecular control of adult nerve repair. Four alternatively spliced transcript variants, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 764 amino-acid changes on canonical ENST00000587303 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTPRS · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTPRS – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 43/612 7% |
| Colorectal Carcinoma | 32/143 22% | 187/3239 6% |
| Gastric Carcinoma | 8/74 11% | 85/1809 5% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Cervical Carcinoma | 5/35 14% | 12/422 3% |
| Hodgkins Lymphoma | 2/16 12% | 3/122 2% |
| Melanoma | 7/210 3% | 68/1899 4% |
| Other Solid Cancers | 6/94 6% | 43/1515 3% |
| Non-Small Cell Lung Carcinoma | 19/304 6% | 30/1390 2% |
| Neuroendocrine Tumour | 7/154 5% | 14/577 2% |
| Unknown | 1/10 10% | 0/29 0% |
| Esophageal Carcinoma | 1/23 4% | 18/769 2% |
| Non-Cancerous | 0/104 0% | 22/830 3% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 55/2550 2% |
| Bladder Carcinoma | 2/58 3% | 19/956 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Plasma Cell Myeloma | 4/44 9% | 3/305 1% |
| Ovarian Carcinoma | 10/109 9% | 10/998 1% |
| Head and Neck Carcinoma | 4/85 5% | 26/1574 2% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 10/810 1% |
| Pancreatic Carcinoma | 6/89 7% | 21/1611 1% |
| Other Sarcomas | 5/69 7% | 7/699 1% |
| Hepatocellular Carcinoma | 0/46 0% | 35/2210 2% |
| Glioma | 7/52 13% | 25/2127 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 21/1592 1% |
| Meningioma | 0/3 0% | 3/252 1% |
Mutation Distribution
Where PTPRS is mutated · all tissues, split by cell line vs tissue
How many mutations in PTPRS were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,489 mutations in PTPRS
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|